How Do CGRPs Work? Key and Lock Analogy

During the 60th Annual American Headache Society (AHS) Scientific Conference in San Francisco, I had the distinct pleasure of sitting down with Dr. David Dodick, professor of neurology and a headache specialist at the Mayo Clinic in Phoenix, Arizona. In part one of this interview, Dr. Dodick discussed the importance of setting realistic expectations on how this new treatment – CGRPs, may reduce migraine frequency. In part two of our discussion, Dr. Dodick explains how CGRP antibodies function like a key and a lock and how future forms of this medication are also promising.

The good news and the bad news

Dr. Dodick candidly explains, “The bad news is you have maybe a 1 in 5 chance of not responding in the right way… The good news is there’s more coming.” Based on his key and lock analogy, there’s hope for those who try the new treatment but may not respond to the “lock antibodies” as they may respond to the “key antibodies” that are developed in the future.

Join the discussion

Want to know how others living with migraine are doing with this new treatment? Check out the discussion in the forums section of the community or ask a question in the Q&A section.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.


View Comments (2)
  • wappaw
    2 months ago

    Just started Aimovig 11/8/2018. Hoping it will reduce the frequency of my migraines. I have been working in the yard which will normally cause shoulder, neck, and back pain; which triggers a migraine. So far the shoulder, neck, and back pain are present, but thankfully no migraine!

  • Mixi
    5 months ago

    It’s very encouraging to know that some new treatment will be available soon….. can’t be soon enough 😉

  • Poll